Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
Keys to the Future: EXIT Realty’s New Chapter in Real Estate
Tomorrow’s World Today® Podcast
27 minutes
6 months ago
Keys to the Future: EXIT Realty’s New Chapter in Real Estate
From closing deals to opening doors to new opportunities, Tami Bonnell, CEO and Co-Chair of EXIT Realty, shares how EXIT’s human-centered approach is changing real estate for good. 🏘️ Featured on: Tomorrow's World Today - S4E06 – Science Behind Relocation Learn more about this topic: Evolution of Real EstatePsychology of Real EstateCollaborate with us! Support the show For more information about the innovations that are shaping tomorrow's world, head to https://tomorrowsworldtoday.com/ To k...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
